Pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia: Japanese Society of Clinical Neuropsychopharmacology treatment algorithms

被引:11
作者
Takeuchi, Hiroyoshi [1 ]
Takekita, Yoshiteru [2 ]
Hori, Hikaru [3 ]
Oya, Kazuto [4 ]
Miura, Itaru [5 ]
Hashimoto, Naoki [6 ]
Yasui-Furukori, Norio [7 ]
机构
[1] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan
[2] Kansai Med Univ, Dept Neuropsychiat, Osaka, Japan
[3] Fukuoka Univ, Sch Med, Dept Psychiat, Fukuoka, Japan
[4] Fujita Hlth Univ, Sch Med, Dept Psychiat, Toyoake, Aichi, Japan
[5] Fukushima Med Univ, Dept Neuropsychiat, Sch Med, Fukushima, Japan
[6] Hokkaido Univ, Grad Sch Med, Dept Psychiat, Sapporo, Hokkaido, Japan
[7] Dokkyo Med Univ, Dept Psychiat, Sch Med, Mibu, Tochigi, Japan
关键词
algorithm; antipsychotics; first episode; schizophrenia; treatment; ANTIPSYCHOTIC MEDICATION; 1ST EPISODE; OPEN-LABEL; RISPERIDONE; PSYCHOSIS; ARIPIPRAZOLE; OLANZAPINE;
D O I
10.1002/hup.2804
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective There are only a few treatment algorithms for first-episode schizophrenia. Moreover, all the algorithms apply to acute treatment, but not maintenance treatment. Therefore, we aimed to develop acute and maintenance treatment algorithms for first-episode schizophrenia. Methods The algorithm committee of the Japanese Society of Clinical Neuropsychopharmacology developed pharmacological treatment algorithms for the acute phase, agitation, and maintenance phase of first-episode schizophrenia. Results The acute treatment algorithm focuses on drug-naive patients with first-episode schizophrenia who are not old or very agitated and recommends first-line treatment with aripiprazole, second- or third-line treatment with risperidone/paliperidone or olanzapine, and fourth-line treatment with clozapine. Long-acting injection of the current antipsychotic agent can be used for poor medication adherence or based on patient preference. The agitation treatment algorithm recommends first-line treatment with lorazepam and second- or third-line treatment with quetiapine or levomepromazine and clearly instructs that the medication used for agitation should be reduced and then discontinued after remission of agitation. The maintenance treatment algorithm recommends the gradual reduction of antipsychotics to the minimum effective dose after remission of positive symptoms. Conclusions We hope that our unique algorithms will be used broadly and will contribute to minimizing patients' burden related to antipsychotic treatment.
引用
收藏
页数:9
相关论文
共 43 条
  • [21] Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia
    Alice Egerton
    Stefan Brugger
    Marie Raffin
    Gareth J Barker
    David J Lythgoe
    Philip K McGuire
    James M Stone
    Neuropsychopharmacology, 2012, 37 : 2515 - 2521
  • [22] A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes
    Robinson, Delbert G.
    Gallego, Juan A.
    John, Majnu
    Petrides, Georgios
    Hassoun, Youssef
    Zhang, Jian-Ping
    Lopez, Leonardo
    Braga, Raphael J.
    Sevy, Serge M.
    Addington, Jean
    Kellner, Charles H.
    Tohen, Mauricio
    Naraine, Melissa
    Bennett, Natasha
    Greenberg, Jessica
    Lencz, Todd
    Correll, Christoph U.
    Kane, John M.
    Malhotra, Anil K.
    SCHIZOPHRENIA BULLETIN, 2015, 41 (06) : 1227 - 1236
  • [23] Widespread white-matter microstructure integrity reduction in first-episode schizophrenia patients after acute antipsychotic treatment
    Meng, Linghui
    Li, Kaiming
    Li, Wenbin
    Xiao, Yuan
    Lui, Su
    Sweeney, John A.
    Gong, Qiyong
    SCHIZOPHRENIA RESEARCH, 2019, 204 : 238 - 244
  • [24] Aripiprazole vs Risperidone for the acute-phase treatment of first-episode psychosis: A 6-week randomized, flexible-dose, open-label clinical trial
    Gomez-Revuelta, Marcos
    Pelayo-Teran, Jose Maria
    Vazquez-Bourgon, Javier
    de la Foz, Victor Ortiz-Garcia
    Mayoral-van Son, Jacqueline
    Ayesa-Arriola, Rosa
    Crespo-Facorro, Benedicto
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2021, 47 : 74 - 85
  • [25] Drug-naive first-episode schizophrenia spectrum disorders: Pharmacological treatment practices in inpatient units in Hunan Province, China
    Zhu, Mengran
    Ferrara, Maria
    Tan, Wenjian
    Shang, Xingbo
    Syed, Sumaiyah
    Zhang, Li
    Qin, Qilin
    Hu, Xinran
    Rohrbaugh, Robert
    Srihari, Vinod H.
    Liu, Zhening
    EARLY INTERVENTION IN PSYCHIATRY, 2021, 15 (04) : 1010 - 1018
  • [26] Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
    Arango, Celso
    Fagiolini, Andrea
    Gorwood, Philip
    Kane, John M.
    Diaz-Mendoza, Sergio
    Sahota, Navdeep
    Correll, Christoph U.
    BMC PSYCHIATRY, 2023, 23 (01)
  • [27] Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: treatment goals and approaches to functional recovery
    Celso Arango
    Andrea Fagiolini
    Philip Gorwood
    John M. Kane
    Sergio Diaz-Mendoza
    Navdeep Sahota
    Christoph U. Correll
    BMC Psychiatry, 23
  • [28] Development and initial evaluation of a clinical prediction model for risk of treatment resistance in first-episode psychosis: Schizophrenia Prediction of Resistance to Treatment (SPIRIT)
    Farooq, Saeed
    Hattle, Miriam
    Kingstone, Tom
    Ajnakina, Olesya
    Dazzan, Paola
    Demjaha, Arsime
    Murray, Robin M.
    Di Forti, Marta
    Jones, Peter B.
    Doody, Gillian A.
    Shiers, David
    Andrews, Gabrielle
    Milner, Abbie
    Nettis, Maria Antonietta
    Lawrence, Andrew J.
    van der Windt, Danielle A.
    Riley, Richard D.
    BRITISH JOURNAL OF PSYCHIATRY, 2024, 225 (03) : 379 - 388
  • [29] An open-label randomised comparison of aripiprazole, olanzapine and risperidone for the acute treatment of first-episode schizophrenia: Eight-week outcomes
    Cheng, Zhang
    Yuan, Yanbo
    Han, Xue
    Yang, Lei
    Cai, Shangli
    Yang, Fude
    Lu, Zheng
    Wang, Chuanyue
    Deng, Hong
    Zhao, Jingping
    Xiang, Yutao
    Correll, Christoph U.
    Yu, Xin
    JOURNAL OF PSYCHOPHARMACOLOGY, 2019, 33 (10) : 1227 - 1236
  • [30] Relapse rates following antipsychotic discontinuation in the maintenance phase after first-episode of schizophrenia: Results of a long-term follow-up study
    Ucok, Alp
    Kara, Ilayda Arjen
    SCHIZOPHRENIA RESEARCH, 2020, 225 : 31 - 38